Astellas Enters Exclusive License Agreement with Evopoint Biosciences for CLDN18.2-targeting ADC XNW27011 June 3, 2025
Sevabertinib (BAY 2927088) granted FDA Priority Review for the treatment of patients with HER2-mutant NSCLC June 3, 2025
Efti with Radiotherapy & KEYTRUDA Meets Primary Endpoint in Ph 2 for Soft Tissue Sarcoma June 3, 2025
Patritumab Deruxtecan BLA for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated NSCLC Voluntarily Withdrawn June 3, 2025
European Commission Approves SC Formulation of Opdivo Across Multiple Solid Tumor Indications June 3, 2025
BioNTech and BMS to Co-Develop and Co-Commercialize BNT327 for Multiple Solid Tumor Types June 3, 2025
Sarah Cannon Research Institute Announces Strategic Alliance with AbbVie to Advance Novel Cancer Therapies June 3, 2025
Lumanity and Parker Institute for Cancer Immunotherapy (PICI) Announce Partnership to Accelerate Immunotherapy Innovation June 3, 2025
First Patient Enrolled in New Ph 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer June 3, 2025
Ivonescimab + Chemo Demonstrates Statistically Significant PFS Improvement and numerical OS improvement in topline data in EGFRm NSCLC after EGFR TKI June 3, 2025
FDA clears IND application for ERAS-4001 for the treatment of patients with KRAS-mutant (KRASm) solid tumors June 3, 2025
FDA Accepts and grants Priority Review of NDA for Ziftomenib in Adults with R/R NPM1-Mutant AML June 3, 2025
FDA grants Regenerative Medicine Advanced Therapy (RMAT) Designation for CAN-2409 for the Treatment of Prostate Cancer June 3, 2025
Imfinzi recommended for approval in the EU by CHMP as perioperative immunotherapy for MIBC June 3, 2025
NMPA Approves Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer June 3, 2025
Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA+ve metastatic HSPC June 3, 2025
